Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520791 · ClinicalTrials.gov registry record · Phase 1
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
A Phase 1 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 20
- Study locations
NCT02520791 is a Phase 1 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 37-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02520791, a Phase 1 study of Recurrent Grade 1 Follicular Lymphoma and Recurrent Grade 2 Follicular Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Anti-ICOS Monoclonal Antibody MEDI-570
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Montefiore Medical Center-Einstein Campus - The Bronx
- Montefiore Medical Center-Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Missouri
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Davis Comprehensive Cancer Center - Sacramento
Connecticut
- Smilow Cancer Center/Yale-New Haven Hospital - New Haven
- Yale University - New Haven
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
Florida
- Moffitt Cancer Center - Tampa
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Kansas
- University of Kansas Clinical Research Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2026-12-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02520791
The ClinicalTrials.gov registry entry for NCT02520791 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 11 other Recurrent Grade 1 Follicular Lymphoma trials with a reported enrollment target (43% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Grade 1 Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02520791 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT02520791 about?
NCT02520791 is a clinical study titled "Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma". This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed...
What is the current status of trial NCT02520791?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-09-13. Estimated completion is 2026-12-24.
What conditions does trial NCT02520791 study?
This clinical trial studies the following conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mycosis Fungoides, Recurrent Grade 3a Follicular Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT02520791?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Anti-ICOS Monoclonal Antibody MEDI-570 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02520791?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02520791 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Grade 1 Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Grade 1 Follicular Lymphoma
All registered trials for this condition
Recurrent Grade 2 Follicular Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.